miR-181a mediates TGF-β-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer

Liver International

Volumn 35, Issue 1, 2015, Pages 240-253

  Brockhausen, Jennifer ^a   Tay, Szun S ^a   Grzelak, Candice A ^a   Bertolino, Patrick ^a   Bowen, David G ^a   d'Avigdor, William M ^a   Teoh, Narcy ^b   Pok, Sharon ^b   Shackel, Nick ^a   Gamble, Jennifer R ^a   Vadas, Mathew ^a   Mccaughan, Geoff W ^a  

^a CENTENARY INSTITUTE   (Australia)

^b The Australian National University   (Australia)

Author keywords

Cirrhosis; EMT; Hepatocellular carcinoma; Hepatocyte; MicroRNA; TGF

Indexed keywords

BIM PROTEIN; MICRORNA; MICRORNA 181A; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; MIRN181 MICRORNA, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PHENOTYPE; UPREGULATION; ANIMAL; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; IN VITRO TECHNIQUES; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICE; MICRORNAS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84920972464     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12517     Document Type: Article

References (37)

1. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-84.
2. Dooley S, Hamzavi J, Ciuclan L, et al. Hepatocyte-specific Smad7 expression attenuates TGF-β-mediated fibrogenesis and protects against liver damage. Gastroenterology 2008; 135: 642-59.
3. Kaimori A, Potter J, Kaimori JY, et al. Transforming growth factor-β1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 2007; 282: 22089-101.
4. Rowe RG, Lin Y, Shimizu-Hirota R, et al. Hepatocyte-derived snail1 propagates liver fibrosis progression. Mol Cell Biol 2011; 31: 2392-403.
5. Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007; 282: 23337-47.
6. Chu AS, Diax R, Hui JJ, et al. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 2011; 53: 1685-95.
7. Taura K, Miura K, Iwaisako K, et al. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 2010; 51: 1027-36.
8. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97-101.
9. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
10. Gregory PA, Bert A, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
11. Gregory PA, Bracken CP, Smith E, et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011; 22: 1686-98.
12. Parikh A, Lee C, Joseph P, et al. MicroRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun 2014; 5; in press.
13. Song MK, Park YK, Ryu JC. Polycyclic aromatic hydrocarbon (PAH)-mediated upregulation of hepatic microRNA-181 family promotes cancer cell migration by targeting MAPK phosphatase-5, regulating the activation of p38 MAPK. Toxicol Appl Pharmacol 2013; 273: 130-9.
14. Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP. TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J Clin Investig 2013; 123: 150-63.
15. Wang B, Hsu SH, Majumder S, et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010; 29: 1787-97.
16. Wang Y, Yu Y, Tsuyada A, et al. Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011; 30: 1470-80.
17. Dahlke MH, Loi R, Warren A, et al. Immune-mediated hepatitis drives low-level fusion between hepatocytes and adult bone marrow cells. J Hepatol 2006; 44: 334-41.
18. Lauer C, Brunner T, Corazza N. The proapoptotic Bcl-2 family member Bim plays a central role during the development of virus-induced hepatitis. J Immunol 2012; 188: 916-22.
19. Ramesh S, Qi XJ, Wildey GM, et al. TGF beta-mediated BIM expression and apoptosis are regulated through SMAD3-dependent expression of the MAPK phosphatase MKP2. EMBO Rep 2008; 9: 990-7.
20. Dooley S, ten Dijke P. TGF-β in progression of liver disease. Cell Tissue Res 2012; 347: 245-56.
21. Hoshino Y, Katsuno Y, Ehata S, Miyazono K. Autocrine TGF-β protects breast cancer cells from apoptosis through reduction of BH3-only protein, Bim. J Biochem 2011; 149: 55-65.
22. Gillings AS, Balmanno K, Wiggins CM, Johnson M, Cook SJ. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J 2009; 276: 6050-62.
23. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25: 3787-800.
24. Tian M, Neil JR, Schiemann WP. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 2011; 23: 951-62.
25. Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-9.
26. Gao W, Shen H, Liu L, et al. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2011; 137: 557-66.
27. Shin KH, Bae SD, Hong HS, et al. MiR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun 2011; 404: 896-902.
28. Gao W, Yu Y, Cao H, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010; 64: 399-408.
29. Ciafrè SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005; 334: 1351-8.
30. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283: 29897-903.
31. Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009; 50: 472-80.
32. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-24.
33. Zhang X, Nie Y, Du Y, et al. MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6. Tumor Biol 2012; 33: 1589-97.
34. Neel JC, Lebrun JJ. Activin and TGF-β regulate expression of the microRNA-181 family to promote cell migration and invasion in breast cancer cells. Cell Signal 2013; 25: 1556-66.
35. Nishimura J, Handa R, Yamamoto H, et al. MicroRNA-181a is associated with poor prognosis of colorectal cancer. Oncol Rep 2012; 28: 2221-6.
36. Grimm D, Pandey K, Nakai H, Storm TA, Kay MA. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol 2006; 80: 426-39.
37. Ikeda M, Sugiyama K, Mizutani T, et al. Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. Virus Res 1998; 56: 157-67.